In contrast, c-MET resulted as a co-lesion with NOTCH 3 and FBXW7 in one of the patients of our analysis, thus suggesting the potential use of Crizotinib, a multi-target tyrosine kinase inhibitor (TKI) in bladder cancer [117] in this mutational setting. This evidence concerns the gene NOTCH3 and urinary bladder cancer.